Hualan Biologicals: Invested Company Receives Notice of Approval for Drug Clinical Trials

Hualan Bioscience announced that on February 25, 2026, its joint venture company Hualan Ankang Biotechnology Co., Ltd. received the "Approval Notification for Drug Clinical Trials" from the National Medical Products Administration. The drug is called Pembrolizumab Injection, classified as a class 3.3 therapeutic biological product, indicated for melanoma, non-small cell lung cancer, esophageal cancer, head and neck squamous cell carcinoma, etc. Clinical trials are approved to be conducted as a biosimilar drug.